```html

Iatrogenic Hyperkalemia – A Patient‑Focused Medical Guide

Overview

Hyperkalemia is an abnormally high level of potassium (K⁺) in the bloodstream, typically defined as a serum potassium concentration >5.0 mmol/L. When the condition results from medical treatment—such as drugs, procedures, or hospital‑based interventions—it is called iatrogenic hyperkalemia. The term “iatrogenic” means “originating from medical care.”

Because potassium is essential for normal nerve, muscle, and cardiac function, even modest elevations can cause serious symptoms, especially in vulnerable patients. Iatrogenic hyperkalemia accounts for a substantial portion of hospital‑acquired electrolyte disorders. Studies from the United States estimate that up to 15 % of in‑hospital hyperkalemia cases are drug‑induced and that the overall incidence of hyperkalemia in hospitalized adults ranges from 1.5 % to 10 % depending on the patient population and definition used (Mayo Clinic Proceedings 2020; JAMA Intern Med 2021).

The condition can affect anyone who receives medical care, but it is most common in:

• Patients with chronic kidney disease (CKD) or acute kidney injury (AKI)
• Elderly individuals (≥65 years) who are often on multiple medications
• Those receiving potassium‑sparing diuretics, renin‑angiotensin‑aldosterone system (RAAS) inhibitors, or intravenous (IV) potassium
• Individuals undergoing major surgery, especially with massive transfusions or cellular blood products

Symptoms

Symptoms of hyperkalemia result from the effect of excess potassium on the neuromuscular and cardiac systems. They can develop gradually or suddenly, and not all patients experience every sign.

General (non‑cardiac) symptoms

• Muscle weakness or fatigue – a feeling of heaviness, especially in the legs.
• Paresthesias – tingling or “pins‑and‑needles” sensations.
• Cramping or muscle twitching – sometimes mistaken for seizures.
• Abdominal discomfort – nausea, vomiting, or constipation.

Cardiac symptoms (most concerning)

• Palpitations – awareness of an irregular heartbeat.
• Chest pain or pressure – can mimic angina.
• Syncope or near‑syncope – fainting due to sudden drops in heart output.
• Shortness of breath – from reduced cardiac output.

Severe, life‑threatening signs

• Sudden cardiac arrest
• Ventricular tachycardia or fibrillation
• Severe bradycardia (heart rate < 40 bpm)

Because cardiac manifestations may appear before any other symptom, routine laboratory monitoring is crucial for patients at risk.

Causes and Risk Factors

Medications that increase potassium

• RAAS inhibitors: ACE inhibitors, ARBs, direct renin inhibitors, aldosterone antagonists (e.g., spironolactone, eplerenone).
• Potassium‑sparing diuretics: amiloride, triamterene.
• NSAIDs: especially when combined with RAAS blockers.
• Beta‑blockers and digoxin (can impair cellular uptake of K⁺).
• IV potassium supplementation – especially rapid infusions (>10 mmol/hr).
• Blood transfusions – stored red cells leak potassium over time.
• Succinylcholine – a depolarizing neuromuscular blocker used in anesthesia.

Procedures and clinical situations

• Massive blood transfusion (>10 units) or rapid infusion of stored blood.
• Cellular lysis: tumor lysis syndrome, rhabdomyolysis, hemolysis.
• Renal replacement therapy (dialysis) interruptions.
• Cardiac surgery with cardiopulmonary bypass (adds potassium from intracellular sources).

Patient‑related risk factors

• Chronic kidney disease (eGFR < 60 mL/min/1.73 m²) or acute kidney injury.
• Diabetes mellitus with hypo‑insulinemia.
• High dietary potassium intake combined with the above.
• Elderly age and polypharmacy.
• Volume depletion or severe dehydration.
• Acidosis (shifts K⁺ out of cells).

Diagnosis

Prompt recognition relies on both clinical suspicion and laboratory testing.

Laboratory tests

• Serum potassium level: measured via venous blood; repeat testing if >5.5 mmol/L.
• Electrolyte panel: sodium, chloride, bicarbonate, creatinine, BUN – to gauge kidney function.
• Arterial blood gas (ABG): detects metabolic acidosis, which can exacerbate hyperkalemia.
• Urine potassium: helpful if kidney function is intact; a low urinary K⁺ suggests reduced excretion.

Electrocardiogram (ECG)

ECG changes are the most immediate indicator of dangerous hyperkalemia and may appear even when serum levels are modestly elevated.

• Peaked (tented) T‑waves
• Prolonged PR interval
• Widened QRS complex
• Sine‑wave pattern (severe)
• Eventually, ventricular arrhythmias or asystole

When to obtain labs

• Within 24 hours of starting any high‑risk medication.
• After major surgery, transfusion, or dialysis.
• If the patient develops any symptoms listed above.
• Routine monitoring for CKD patients at least every 3–6 months (KDIGO guidelines).

Treatment Options

Treatment aims to (1) stabilize the cardiac membrane, (2) shift potassium into cells, and (3) eliminate excess potassium from the body. The choice depends on severity, underlying cause, and renal function.

1. Cardiac membrane stabilization

• IV calcium gluconate (10 mL of 10 % solution) or calcium chloride (1 g): given over 5–10 minutes. Acts within minutes, buying time for other measures. Does not lower serum K⁺.

2. Shifting potassium intracellularly

• Insulin + glucose: Regular insulin 10 U IV + 25 g dextrose (50 mL of 50 % dextrose). Effect starts in 15 min, peaks at 30–60 min, lasts ~4–6 hours.
• Beta‑2 agonists: Albuterol nebulized 10–20 mg over 10 minutes (or high‑dose inhaled form). Especially useful in asthma patients.
• Sodium bicarbonate: 50 mmol IV for patients with concurrent metabolic acidosis; modest K⁺ shift.

3. Removing potassium from the body

• Loop or thiazide diuretics: increase urinary K⁺ excretion (if renal function allows).
• Potassium‑binding resins: Sodium polystyrene sulfonate (Kayexalate) – oral or rectal; newer agents patiromer and sodium zirconium cyclosilicate (ZS‑9) have better tolerability.
• Hemodialysis: fastest and most definitive removal, indicated for severe hyperkalemia (≥6.5 mmol/L), refractory cases, or when renal function is poor.

4. Addressing the underlying cause

• Discontinue or dose‑adjust offending medications (e.g., stop spironolactone).
• Treat AKI or optimize volume status.
• Adjust nutrition – lower potassium‑rich foods if needed.

Medication dosing – quick reference

Intervention	Typical Dose	Onset	Duration
Calcium gluconate 10 %	10 mL IV over 5 min	1–3 min	30–60 min
Insulin + 50 % dextrose	10 U insulin + 25 g glucose	15 min	4–6 h
Albuterol nebulizer	10–20 mg (2.5 mg vials ×4)	30 min	2–4 h
Patiromer	8.4 g PO daily	7 h	24 h
ZS‑9	10 g PO once	1 h	24 h

Living with Iatrogenic Hyperkalemia

Even after the acute episode resolves, many patients need ongoing strategies to prevent recurrence.

Medication management

• Maintain an updated medication list; ask your pharmacist or provider to review for potassium‑raising drugs.
• Never restart a previously discontinued RAAS inhibitor without lab confirmation that potassium is <5.0 mmol/L.

Dietary considerations

• Limit high‑potassium foods: bananas, oranges, potatoes, tomatoes, avocados, nuts, and dried fruit.
• Favor low‑potassium alternatives such as apples, berries, cauliflower, white rice, and pasta.
• Cooking techniques—boiling vegetables and discarding the water—can reduce potassium content by up to 50 %.

Monitoring

• Check serum potassium at least monthly if you have CKD or are on a potassium‑sparing drug.
• Use home blood pressure cuffs and keep a log; sudden hypertension or edema may hint at fluid shifts affecting potassium.
• Report any new weakness, palpitations, or irregular heartbeats promptly.

Lifestyle tips

• Stay well‑hydrated unless fluid restriction is prescribed.
• Avoid over‑the‑counter potassium supplements or “salt substitutes” (often contain KCl).
• Inform all healthcare providers (dentist, urgent care, etc.) about your hyperkalemia history.

Prevention

Preventing iatrogenic hyperkalemia hinges on careful prescribing, vigilant monitoring, and patient education.

• Risk‑stratified prescribing: Use lower doses or alternative agents in CKD, elderly, or those on multiple potassium‑affecting meds.
• Electronic health record alerts: Many institutions have built‑in warnings when a high‑risk combination is ordered.
• Laboratory safety nets: Set automatic repeat potassium checks 24–48 hours after starting a new RAAS inhibitor.
• Patient counseling: Provide printed material on foods, medication timing, and signs that need urgent attention.
• Dialysis planning: For end‑stage renal disease, ensure regular dialysis sessions; avoid missed treatments.

Complications

If not corrected, hyperkalemia can cause severe, sometimes irreversible, organ damage.

• Cardiac arrhythmias – the most common cause of sudden cardiac death in hospitalized patients with hyperkalemia.
• Muscle paralysis – severe weakness can impair respiration, leading to respiratory failure.
• Acute kidney injury worsening – high potassium may reflect or exacerbate renal perfusion problems.
• Metabolic acidosis – especially in tumor‑lysis or rhabdomyolysis syndromes; acidemia further shifts K⁺ out of cells.

When to Seek Emergency Care

Key Take‑aways

• Iatrogenic hyperkalemia is a common, sometimes preventable, hospital‑acquired problem.
• High‑risk drugs, renal impairment, and rapid potassium administration are the main culprits.
• Early ECG changes and repeat serum potassium measurements are essential for diagnosis.
• Treatment follows a three‑step hierarchy: stabilize the heart, shift potassium intracellularly, then eliminate excess potassium.
• Long‑term management includes medication review, dietary moderation, regular lab monitoring, and patient education.
• Any sudden cardiac or neuromuscular symptom should prompt emergency evaluation.

For personalized advice, discuss your medication list and lab results with your primary care physician or a nephrologist. Reliable sources for further reading include the Mayo Clinic, CDC, NIH National Kidney Foundation, WHO, and peer‑reviewed journals such as Kidney International and American Journal of Medicine.

```